Silence Therapeutics plc

Board/Management Information • Jul 18, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3962E

Silence Therapeutics PLC

18 July 2016

Grant of share options to Chief Financial Officer

18 July 2016

Pursuant to the announcement of 24 May 2016, Silence Therapeutics plc ("Silence" or the "Company"), AIM: SLN, a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, confirms that David Ellam starts today as Chief Financial Officer and a director on the Board of the Company.

David has today been awarded 200,000 options, vesting after 3 years and at a strike price of 110.62p, being the closing price of the Company's shares on Friday 15 July 2016.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1.	Details of PDMR / person closely associated with them ("PCA")
a)	Name	David Ellam
b)	Position / status	Chief Financial Officer
c)	Initial notification / amendment	Initial notification
2.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument	Options over ordinary shares
b)	Nature of the transaction	Grant of options
c)	Price(s) and volume(s)	Price (s)	Volume(s)
110.62p	200,000
d)	Aggregated information -     Aggregated volume -     Price	N/A - single transaction
e)	Date of the transaction	18 July 2016
f)	Place of the transaction	London Stock Exchange, AIM

Enquiries:

Silence Therapeutics plc      

Ali Mortazavi, Chief Executive Officer

David Ellam, Chief Financial Officer

Tel: +44 (0)20 3457 6900

Canaccord Genuity Limited (Nominated Adviser and Joint Broker)

Dr Julian Feneley/Henry Fitzgerald-O'Connor/Emma Gabriel

Tel: +44 (0)20 7523 8350

Peel Hunt LLP (Joint Broker)

James Steel/Oliver Jackson

Tel: +44 (0)20 7418 8900

Media Enquiries:

FTI Consulting          

Simon Conway/Brett Pollard/Stephanie Cuthbert

Tel: +44 (0) 20 3727 1000

Notes to Editors:

About Silence Therapeutics Plc

Our technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. This technology can selectively silence or replace any gene in the genome, modulating gene expression up as well as down in a variety of organs and cell types, in vivo. We have developed proprietary modifications to improve the robustness of RNA sequences, together with advanced liposomal chemistries to enhance the delivery of therapeutics.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHDDGDRDBBBGLR